Spinal Muscular Atrophy Therapeutics Pipeline to Receive More R&D Investments in the Future: P&S Market Research

NEW YORK, March 30, 2018 -- According to a new research report titled “Spinal Muscular Atrophy Therapeutics Pipeline Analysis, 2017” published by P&S Market Research, Spinal muscular atrophy currently exhibits a pipeline with 16 drug candidates.

Request for Sample Copy of this Research Report: https://www.psmarketresearch.com/market-analysis/spinal-muscular-atrophy-therapeutics-pipeline-analysis/report-sample

The study analyzed that the therapeutics pipeline comprises approximately 16 drug candidates in different stages of development. Spinal muscular atrophy is defined as the inherited genetic disease that is characterized by a failure of nerve cells called motor neurons. Motor neurons are responsible to accept the nerve impulses transmitted from the brain to the spinal cord and transmit the impulses to the muscle with the help of peripheral nerves. The loss of motor neurons leads to muscle weakness in muscles that are closest to the trunk of the body such as back, hips and shoulders.

Imago Pharmaceuticals, Inc. is using nucleic acid therapeutics technology platform for the treatment of spinal muscular atrophy. Nucleic acid therapeutics technology includes large and innovative class of drugs that can modulate the function of target ribonucleic acid, or RNA, to ultimately affect the production of disease-associated proteins. Nucleic acid therapeutics comprise of complex mixtures of various chemical entities known as stereoisomers. Some stereoisomers in these mixtures have therapeutic effects, while others are less beneficial or contribute to undesirable side effects. Uncontrolled stereoisomer drug mixtures can lead to suboptimal efficacy and increased risk and safety concerns.

Browse Full Report with detailed TOC on “Spinal Muscular Atrophy Therapeutics Pipeline” at: https://www.psmarketresearch.com/market-analysis/spinal-muscular-atrophy-therapeutics-pipeline-analysis

Some of the other key players developing drugs for the treatment of spinal muscular atrophy include Cytokinetics, Inc., F. Hoffman La-Roche Ltd, WAVE Life Sciences Ltd. and others.

More Reports Published by P&S Market Research

PI3K Inhibitors Pipeline Analysis - https://www.psmarketresearch.com/market-analysis/phosphoinositide-3-kinase-inhibitor-pipeline-analysis

Ulcerative Colitis Therapeutics Pipeline Analysis - https://www.psmarketresearch.com/market-analysis/ulcerative-colitis-pipeline-analysis

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: [email protected]

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook